CAS 1884461-72-6

Ensifentrine

CAS: 1884461-72-6

Fórmula: C₂₆H₃₁N₅O₄

Pureza: 98%

Forma y color: Solid

Peso molecular: 477.5554

Ref: IN-DA01V7CR

Ensifentrine

CAS: 1884461-72-6

(E)-1-(2-(2-(Mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl)ethyl)urea

Fórmula: C₂₆H₃₁N₅O₄

Pureza: 98+%

Peso molecular: 477.56

Ref: IN-DG01492811

Ensifentrine

CAS: 1884461-72-6

Ensifentrine

Fórmula: C₂₆H₃₁N₅O₄

Pureza: ≥98%

Peso molecular: 477.56

Ref: 54-BUP07823

Ensifentrine

CAS: 1884461-72-6

Fórmula: C₂₆H₃₁N₅O₄

Peso molecular: 477.57

Ref: 4Z-E-225001

Ensifentrine

CAS: 1884461-72-6

Ensifentrine (Ensifentrinum) is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that

Fórmula: C₂₆H₃₁N₅O₄

Pureza: 99.76% - 99.94%

Forma y color: Green Solid

Peso molecular: 477.56

Ref: TM-T25376

Ensifentrine

CAS: 1884461-72-6

Fórmula: C₂₆H₃₁N₅O₄

Peso molecular: 477.56

Ref: ST-EA-CP-E78000

RPL 554

Producto controlado

CAS: 1884461-72-6

Fórmula: C₂₆H₃₁N₅O₄

Forma y color: Neat

Peso molecular: 477.555

Ref: TR-R700940

Ensifentrine

CAS: 1884461-72-6

Ensifentrine is an orally active, long-acting bronchodilator. It is a phosphodiesterase inhibitor that relaxes the smooth muscle in the airways and reduces the inflammation of the bronchial tubes. Ensifentrine has been shown to be effective in patients with chronic bronchitis and oesophageal varices. Ensifentrine is administered by inhalation as a nebulized solution. The recommended dose for adults with chronic bronchitis is 20 mg twice daily for 4 weeks, followed by 20 mg once daily for 8 weeks. The recommended dose for patients with oesophageal varices is 40 mg twice daily for 4 weeks, followed by 40 mg once daily for 8 weeks. Ensifentrine has not been studied in children less than 18 years old or pregnant women.

Fórmula: C₂₆H₃₁N₅O₄

Pureza: Min. 95%

Peso molecular: 477.6 g/mol

Ref: 3D-JAD46172